Hypoxia-inducible factor (HIF)-1α predicts a poor response to primary chemo-endocrine therapy and disease-free survival in primary human breast cancer
Stephen B. Fox(Peter MacCallum Cancer Centre), Daniele Generali(University of Trieste), Valeria Gandolfi(Istituti Ospitalieri di Cremona), Alberto Bottini(University of Genoa), Alessandra Bersiga(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Sergio Aguggini(Istituti Ospitalieri di Cremona), Luigi Dogliotti(Aarhus University Hospital), Adrian L. Harris(University of Oxford), Manuela Milani(Humanitas University), Simone Bonardi(Istituti Ospitalieri di Cremona), Alfredo Berruti(Surgical Specialties (Canada)), Leticia Campo(University of Oxford), Simon Wigfield(John Radcliffe Hospital)
Cancer Research
April 15, 2006
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k